RNF121 Inhibitors
Chemical inhibitors of RNF121 target the protein's ubiquitin-proteasome system (UPS), which is responsible for protein degradation and turnover. Proteasome inhibitors such as MG132, Lactacystin, Bortezomib, Epoxomicin, Clasto-Lactacystin β-lactone, Marizomib, Oprozomib, Carfilzomib, and Delanzomib interfere with the proteasome's ability to degrade ubiquitinated proteins. This leads to an accumulation of these proteins within the cell, which can include ubiquitinated RNF121 or its substrates. The build-up of polyubiquitinated proteins effectively hinders RNF121's function, as it relies on the proteasome to regulate protein levels and maintain cellular homeostasis. Inhibition of the proteasome thus disrupts RNF121's role in tagging proteins for degradation, leading to an inhibition of its ubiquitin ligase activity.
Additionally, MLN4924 inhibits the NEDD8-activating enzyme, which is crucial for the neddylation process that modulates the activity of ubiquitin ligase complexes, including RNF121. By inhibiting this upstream activator, MLN4924 indirectly impedes the ubiquitin ligase activity of RNF121. Auranofin, although not a direct proteasome inhibitor, has been shown to inhibit the proteasome indirectly, which similarly leads to an accumulation of ubiquitinated substrates. This accumulation can affect RNF121's function by saturating the protein with unprocessed substrates, thereby inhibiting its role in cellular protein quality control. Withaferin A also interferes with proteasomal activity, contributing to the increase in ubiquitinated proteins that may involve RNF121, thus inhibiting its function by preventing the normal processing and turnover of these proteins. Each of these chemicals disrupts the UPS in a way that can inhibit the functional activity of RNF121, emphasizing their role in the potential regulation of this protein's ubiquitin ligase activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor that can inhibit the degradation of ubiquitinated proteins, potentially leading to the accumulation of ubiquitinated RNF121 and preventing its normal function. | ||||||
Withaferin A | 5119-48-2 | sc-200381 sc-200381A sc-200381B sc-200381C | 1 mg 10 mg 100 mg 1 g | $130.00 $583.00 $4172.00 $20506.00 | 20 | |
Withaferin A acts as an inhibitor of the proteasomal pathway. By inhibiting proteasomal activity, it can lead to an accumulation of polyubiquitinated proteins, which may include RNF121, thereby inhibiting its function. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Lactacystin is a specific inhibitor of the proteasome that can lead to the build-up of ubiquitinated proteins, including potentially ubiquitinated RNF121, thereby inhibiting its functional ubiquitin-ligase activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib selectively inhibits the 26S proteasome, which could lead to an accumulation of ubiquitin-conjugated proteins including RNF121, hence inhibiting its normal functional turnover and activity. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Epoxomicin is a selective proteasome inhibitor that can cause an increase in ubiquitinated proteins by preventing their degradation, which could include RNF121, thereby inhibiting its function by accumulation. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
MLN4924 inhibits the NEDD8-activating enzyme, which is necessary for the neddylation process that regulates the activity of ubiquitin ligase complexes. This inhibition can lead to reduced ubiquitin ligase activity of RNF121. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
Oprozomib inhibits the activity of the proteasome, which could lead to the accumulation of ubiquitinated substrates of RNF121, thus inhibiting the protein's functional activity by preventing the normal turnover of these substrates. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $41.00 | ||
Carfilzomib is a selective proteasome inhibitor. By inhibiting the proteasome, it can lead to an accumulation of proteins targeted for degradation by RNF121, which may inhibit RNF121's normal ubiquitin ligase function by substrate accumulation. | ||||||
Delanzomib, free base | 847499-27-8 | sc-396774 sc-396774A | 5 mg 10 mg | $160.00 $300.00 | ||
Delanzomib is a proteasome inhibitor that can disrupt the normal degradation pathway of ubiquitinated proteins, which could include substrates of RNF121, resulting in inhibition of RNF121's role in protein turnover. | ||||||
Auranofin | 34031-32-8 | sc-202476 sc-202476A sc-202476B | 25 mg 100 mg 2 g | $153.00 $214.00 $4000.00 | 39 | |
Auranofin has been shown to inhibit the proteasome indirectly. By this action, it can lead to the accumulation of ubiquitinated proteins, potentially including the substrates of RNF121, thereby inhibiting RNF121's ubiquitin ligase activity by preventing the proper degradation of its substrates. | ||||||